Inhibition of Human Amylin Aggregation: <i>In Silico</i> and <i>In Vitro</i> Studies.

ABSTRACT: Human islet amyloid polypeptide (hIAPP), also termed amylin, is an endocrine hormone that plays a key role in regulating blood glucose levels. Pathological conformational changes in amylin can lead to its aggregation into amyloid deposits, which are significant markers in the development of type 2 diabetes (T2D) and Alzheimer's disease (AD). In this study, we explored 1-benzylamino-2-hydroxyalkyl derivatives as potential amylin aggregation inhibitors. These compounds have previously demonstrated activity against amyloid-β aggregation in AD. We conducted ThT and DLS assays to identify compounds 18 and 22 as the most active derivatives, inhibiting amylin aggregation with IC₅₀ values of 3.04 and 2.71 μM, respectively. These compounds preserved small-sized oligomers, which exhibited

SUBMITTER: Mizgalska K 

PROVIDER: S-EPMC12612973 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature